Team:WPI-Worcester/Future-Applications

From 2014.igem.org

(Difference between revisions)
 
(12 intermediate revisions not shown)
Line 11: Line 11:
@import "/wiki/skins/common/shared.css?270";
@import "/wiki/skins/common/shared.css?270";
@import "/wiki/skins/igem/main.css?270";
@import "/wiki/skins/igem/main.css?270";
-
/*]]>*/</style>
+
/*]]>*/
 +
#contentSub, #footer-box, #catlinks, #search-controls, #p-logo, .printfooter, .firstHeading,.visualClear {display: none;}
 +
</style>
<link rel="stylesheet" type="text/css" media="print" href="/wiki/skins/common/commonPrint.css?270" />
<link rel="stylesheet" type="text/css" media="print" href="/wiki/skins/common/commonPrint.css?270" />
<!--[if lt IE 5.5000]><style type="text/css">@import "/wiki/skins/igem/IE50Fixes.css?270";</style><![endif]-->
<!--[if lt IE 5.5000]><style type="text/css">@import "/wiki/skins/igem/IE50Fixes.css?270";</style><![endif]-->
Line 153: Line 155:
H8 {
H8 {
-
       font-family: Georgia;
+
       font-family: Arial;
       text-transform: none;
       text-transform: none;
       text-decoration: none;
       text-decoration: none;
       text-align: left;
       text-align: left;
-
       color: #AC2B37;
+
       color: #000000;
-
       font-size: 12pt;
+
       font-size: 10pt;
-
 
+
}
H9 {
H9 {
       font-family: Georgia;
       font-family: Georgia;
Line 165: Line 167:
       text-decoration: none;
       text-decoration: none;
       text-align: left;
       text-align: left;
-
       color: #AC2B37;
+
       color: #A9b0b7;
-
       font-size: 14pt;
+
       font-size: 16pt;
     }
     }
Line 564: Line 566:
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Team">Bios</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Team">Bios</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Team-Gallery">Team Gallery</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Team-Gallery">Team Gallery</a></li>
 +
<li><a href="https://igem.org/Team.cgi?id=1423">Official Team Page</a></li>
</ul>
</ul>
</li>
</li>
Line 569: Line 572:
<li><a href="#"><center><img src="https://static.igem.org/mediawiki/2014/4/41/WPI_Project_Link.png"/></center><p>Project</p></a>  
<li><a href="#"><center><img src="https://static.igem.org/mediawiki/2014/4/41/WPI_Project_Link.png"/></center><p>Project</p></a>  
<ul>  
<ul>  
-
    <li><a href="https://2014.igem.org/Team:WPI-Worcester/Overview">Project Overview and Abstract</a></li>  
+
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Motivation">Motivation</a></li>
             <li><a href="https://2014.igem.org/Team:WPI-Worcester/Background">Background</a></li>
             <li><a href="https://2014.igem.org/Team:WPI-Worcester/Background">Background</a></li>
-
            <li><a href="https://2014.igem.org/Team:WPI-Worcester/Motivation">Motivation</a></li>
+
    <li><a href="https://2014.igem.org/Team:WPI-Worcester/Overview">Project Overview</a></li>
    <li><a href="https://2014.igem.org/Team:WPI-Worcester/Future-Applications">Future Applications</a></li>
    <li><a href="https://2014.igem.org/Team:WPI-Worcester/Future-Applications">Future Applications</a></li>
Line 581: Line 584:
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Our-Construct">Our Construct</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Our-Construct">Our Construct</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Proof-of-Principle">Proof of Principle</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Proof-of-Principle">Proof of Principle</a></li>
-
<li><a href="https://2014.igem.org/Team:WPI-Worcester/ATF1">Biobrick Characterization</a></li>
+
<li><a href="https://2014.igem.org/Team:WPI-Worcester/ATF1">Better BioBrick Characterization</a></li>
-
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Biobricks">Biobricks</a></li>  
+
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Biobricks">BioBricks</a></li>  
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Medal-Fulfillment">Medal Fulfillment</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Medal-Fulfillment">Medal Fulfillment</a></li>
Line 588: Line 591:
</li>
</li>
-
<li><a href="#"><center><img src="https://static.igem.org/mediawiki/2014/7/7e/WPI_Notes_Link.png"/></center></<p></p><p>Notebook</p></a>
+
<li><a href="#"><center><img src="https://static.igem.org/mediawiki/2014/7/7e/WPI_Notes_Link.png"/></center><p>Notebook</p></a>
<ul>
<ul>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Notebook">Weekly Log</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Notebook">Weekly Log</a></li>
Line 599: Line 602:
<li><a href="#"><center><img src="https://static.igem.org/mediawiki/2014/d/d4/WPI_Safety_Link.png"/></center><p>Practices</p></a>  
<li><a href="#"><center><img src="https://static.igem.org/mediawiki/2014/d/d4/WPI_Safety_Link.png"/></center><p>Practices</p></a>  
<ul>
<ul>
 +
                <li><a href="https://2014.igem.org/Team:WPI-Worcester/Outreach">Outreach</a></li>
             <li><a href="https://2014.igem.org/Team:WPI-Worcester/Survey">Survey</a></li>
             <li><a href="https://2014.igem.org/Team:WPI-Worcester/Survey">Survey</a></li>
-
            <li><a href="https://2014.igem.org/Team:WPI-Worcester/Outreach">Outreach</a></li>
 
  <li><a href="https://2014.igem.org/Team:WPI-Worcester/Collaborations">Collaborations</a></li>
  <li><a href="https://2014.igem.org/Team:WPI-Worcester/Collaborations">Collaborations</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Interlab">Interlab Study</a></li>
<li><a href="https://2014.igem.org/Team:WPI-Worcester/Interlab">Interlab Study</a></li>
Line 622: Line 625:
</br>
</br>
-
<h4>Future Applications</h4><p>While CAEV was a good starting point, our project can be applied to virtually any other disease. The only requirements for using this construct as a diagnostic tool are that the disease to be diagnosed is caused by a pathogen, the pathogen produces a known antigen, and the host organism produces antibodies to the antigen. Once the target disease is chosen, the sequence for the antigen can easily be placed into the construct in CAEV’s place to create <i>E. coli</i> that produce the antigen of interest on the surface of the membrane. This can be used to diagnose the disease in the same agglutination test designed for the original project by combining the bacteria with plasma from the host organism in a 96-well plate and letting it sit overnight. Currently, our team has identified two diseases that could benefit greatly from our diagnostic tool: Ebola, dengue fever.</p>
+
<h4>Future Applications</h4><p>While CAEV was a good starting point, our project can be applied to virtually any other disease. The only requirements for using this construct as a diagnostic tool are that the disease to be diagnosed is caused by a pathogen, the pathogen produces a known antigen, and the host organism produces antibodies to the antigen. Once the target disease is chosen, the sequence for the antigen can easily be placed into the construct in CAEV’s place to create <i>E. coli</i> that produce the antigen of interest on the surface of the membrane. This can be used to diagnose the disease in the same agglutination test designed for the original project by combining the bacteria with plasma from the host organism in a 96-well plate and letting it sit overnight. Currently, our team has identified two diseases that could benefit greatly from our diagnostic tool: Ebola, and dengue fever.</p>
<p><center><img src="https://static.igem.org/mediawiki/2014/thumb/6/66/WPI_GeneralAntigen.png/800px-WPI_GeneralAntigen.png"/></p></center>
<p><center><img src="https://static.igem.org/mediawiki/2014/thumb/6/66/WPI_GeneralAntigen.png/800px-WPI_GeneralAntigen.png"/></p></center>
-
<p>Ebola is difficult to diagnose because it can take an infected individual up to 21 days to start displaying symptoms1, and once shown, initial symptoms are ubiquitous, resembling the flu2. Being able to diagnose Ebola early and accurately would allow doctors to isolate the individual and provide therapeutic treatments sooner, both decreasing the likeliness of the virus spreading and increasing the chances that someone infected will survive.</p>
+
<p>Ebola is difficult to diagnose because it can take an infected individual up to 21 days to start displaying symptoms<sup>[1]</sup>, and once shown, initial symptoms are ubiquitous, resembling the flu<sup>[2]</sup>. Being able to diagnose Ebola early and accurately would allow doctors to isolate the individual and provide therapeutic treatments sooner, both decreasing the likeliness of the virus spreading and increasing the chances that someone infected will survive.</p>
-
<p>The symptoms of dengue fever also resemble those of other illnesses, and it is easily confused with malaria and typhoid fever3. There is no known cure for dengue fever, and the only effective treatment currently known is fluid replacement therapy, which only works if the disease is detected very early4.  While it is possible to diagnose dengue fever, the test results often come back when it is already too late to help the patient3. Our diagnostic tool could fix this problem, as the only things required would be the  <i>E. coli</i> expressing dengue fever antigens and a blood sample from a potentially infected individual, allowing a diagnostic result to be determined overnight.  
+
<p>The symptoms of dengue fever also resemble those of other illnesses, and it is easily confused with malaria and typhoid fever<sup>[3]</sup>. There is no known cure for dengue fever, and the only effective treatment currently known is fluid replacement therapy, which only works if the disease is detected very early<sup>[4]</sup>.  While it is possible to diagnose dengue fever, the test results often come back when it is already too late to help the patient<sup>[3]</sup>. Our diagnostic tool could fix this problem, as the only things required would be the  <i>E. coli</i> expressing dengue fever antigens and a blood sample from a potentially infected individual, allowing a diagnostic result to be determined overnight.  
</p>
</p>
 +
</br>
 +
<p><h9>References</h9></p>
 +
<h8><p>[1] http://www.cdc.gov/vhf/ebola/symptoms/index.html</p>
 +
<p>[2] http://www.cdc.gov/vhf/ebola/diagnosis/index.html</p>
 +
<p>[3] http://www.mayoclinic.org/diseases-conditions/dengue-fever/basics/tests-diagnosis/con-20032868</p>
 +
<p>[4] http://www.cdc.gov/dengue/symptoms/index.html</p></h8>
 +
</br>
</br>
</br>
</br>
</br>
</br>
</html>
</html>

Latest revision as of 22:45, 17 October 2014

Team:WPI-Worcester - 2014.igem.org

 

Team:WPI-Worcester

From 2014.igem.org


Future Applications

While CAEV was a good starting point, our project can be applied to virtually any other disease. The only requirements for using this construct as a diagnostic tool are that the disease to be diagnosed is caused by a pathogen, the pathogen produces a known antigen, and the host organism produces antibodies to the antigen. Once the target disease is chosen, the sequence for the antigen can easily be placed into the construct in CAEV’s place to create E. coli that produce the antigen of interest on the surface of the membrane. This can be used to diagnose the disease in the same agglutination test designed for the original project by combining the bacteria with plasma from the host organism in a 96-well plate and letting it sit overnight. Currently, our team has identified two diseases that could benefit greatly from our diagnostic tool: Ebola, and dengue fever.

Ebola is difficult to diagnose because it can take an infected individual up to 21 days to start displaying symptoms[1], and once shown, initial symptoms are ubiquitous, resembling the flu[2]. Being able to diagnose Ebola early and accurately would allow doctors to isolate the individual and provide therapeutic treatments sooner, both decreasing the likeliness of the virus spreading and increasing the chances that someone infected will survive.

The symptoms of dengue fever also resemble those of other illnesses, and it is easily confused with malaria and typhoid fever[3]. There is no known cure for dengue fever, and the only effective treatment currently known is fluid replacement therapy, which only works if the disease is detected very early[4]. While it is possible to diagnose dengue fever, the test results often come back when it is already too late to help the patient[3]. Our diagnostic tool could fix this problem, as the only things required would be the E. coli expressing dengue fever antigens and a blood sample from a potentially infected individual, allowing a diagnostic result to be determined overnight.


References

[1] http://www.cdc.gov/vhf/ebola/symptoms/index.html

[2] http://www.cdc.gov/vhf/ebola/diagnosis/index.html

[3] http://www.mayoclinic.org/diseases-conditions/dengue-fever/basics/tests-diagnosis/con-20032868

[4] http://www.cdc.gov/dengue/symptoms/index.html